Ferritarg is a rabbit polyclonal antibody that is coupled with either 111In for diagnostic imaging or 90Y for therapy and is directed against acidic ferritin. In July 2003, 90Y-Ferritarg was granted orphan drug status in the EU for the treatment of Hodgkin’s disease and in September 2006 by the FDA.
Ferritin is produced by most cells in the human body and the protein’s function is to bind and store iron. Ferritin is upregulated in cancer cells allowing differentiation from normal cells with Ferritin as an antigen. 90Y-Ferritarg has been developed initially for the treatment of refractory Hodgkin’s disease (HD). However, the product has not progressed since 2008.